SBC Medical Conducts Expert Session with Global KOL to Enhance Advanced Regenerative Medicine Delivery
Enhancing the Provision Framework for Regenerative Aesthetic Healthcare Through the Advanced Operation of Next-Generation Injection Devices
IRVINE, Calif. -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the successful completion of a specialized educational program focused on the systematic sharing and advancement of cutting-edge aesthetic medical technologies. As part of this initiative, the Company hosted Dr. Kim Sang-yub, an internationally recognized Key Opinion Leader (KOL) in regenerative skin medicine, as an advisor, for an expert session on the South Korean-developed skin booster "Juvelook" and the next-generation injector "CUREJET." Five physicians from the Company’s affiliated "Shonan Beauty Clinic" and "NEO Skin Clinic" completed the curriculum and were awarded certificates of completion, signifying their mastery of the technology.
"Juvelook" is an injectable formulation combining Poly-D, L-Lactic Acid (PDLLA) and Hyaluronic Acid. Unlike traditional fillers designed for temporary volume enhancement, Juvelook is gaining significant global attention as a regenerative treatment that stimulates natural collagen production to address skin texture concerns, including enlarged pores, fine lines, and acne scars. This growth is driven by the increasing global demand for "natural-looking results" and "minimally invasive, tissue-regenerative therapies."
A critical component in consistently achieving optimal therapeutic outcomes is "CUREJET," a state-of-the-art, needle-free injector. Utilizing electromagnetic-driven micro-jet technology to deliver formulations into the dermis, CUREJET is designed to reduce patient discomfort compared to traditional needle injections. Furthermore, its ability to precisely control the depth and volume of delivery allows for highly customized treatments tailored to individual skin conditions. The effective integration and operation of this device require both a deep understanding of formulation characteristics and advanced technical proficiency. The session covered a range of topics, including theoretical frameworks.
SBC Medical remains committed to the continuous integration of advanced medical insights from around the world and the advancement of knowledge and technical standards through specialized education. In the ever-evolving field of aesthetic medicine, the Company rigorously pursues safety and reproducibility under its own stringent verification framework, while flexibly adopting new treatments leveraging the latest technologies. The Company will continue to strive for excellence in safety, transparency, and the delivery of sustainable medical value in alignment with global standards.
About Dr. Kim Sang-yub
Dr. Kim Sang-yub is the Representative Director of J.F. Cell CLINIC (Seoul, South Korea). He graduated from Yonsei University College of Medicine and earned his Ph.D. from the same institution. A member of the Korean Dermatological Association, he is a specialist with over 20 years of clinical experience in dermatology and regenerative medicine. As a global KOL for injectable therapies, he actively provides sessions to medical professionals worldwide and speaks at international conferences.
Official Website: https://www.jfclinic.com/main/main.html
About SBC Medical Group Holdings Incorporated
SBC Medical Group Holdings Incorporated is a comprehensive medical group operating a wide range of franchise businesses across diverse medical fields, including advanced aesthetic medicine, dermatology, orthopedics, fertility treatment, dentistry, AGA (hair restoration), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000® Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose “Contributing to the well-being of people around the world through medical innovation,” SBC Medical Group Holdings Incorporated continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.
For more information, visit https://sbc-holdings.com/
For more insights and updates from SBC Holdings, follow us on LinkedIn
Contacts
SBC Medical Group Holdings Incorporated
Hikaru Fukui / Head of IR Department E-mail: ir@sbc-holdings.com
ICR LLC (US Time)
Bill Zima / Managing Partner E-mail: bill.zima@icrinc.com